Summary of Value-Based Healthcare

Looking for the report?
We have the summary! Get the key insights in just 5 minutes.

Value-Based Healthcare summary
Start getting smarter:
or see our plans

Rating

7

Qualities

  • Innovative
  • Overview
  • Eye Opening

Recommendation

The system of how medical care providers get reimbursed has undergone – and is continuing to undergo – tremendous change. Under the umbrella of “value-based health care” (VBH), the quality of patients’ case results determines the payments to medical providers and health care suppliers – rather than the quantity of tests, procedures or medications a patient receives. Experts at the Economist Intelligence Unit succinctly describe how these changes will affect the big pharmaceutical companies that create and market medications to millions of people. Their report offers compelling examples of how these firms can cope with and benefit from VBH. getAbstract recommends this illuminating report on the shake-up in health care to pharma professionals, health care providers and suppliers, as well as entrepreneurs and investors in the medical arena.

About the Author

The Economist Intelligence Unit Healthcare provides information to aid health care providers, suppliers, payers and others in developing research- and evidence-based business plans.

 

Summary

The New World

Changes in the health care industry radically affect “health care funding” – the basis on which reimbursers pay medical and drug costs. Under “value-based health care” (VBH), “patient outcomes” are the standard for payment. Industry experts see value-based health care as a positive trend, but pharmaceutical firms view VBH as a threat.

Developing, producing, gaining approval for and marketing drugs is expensive; with VBH, pharma firms now must devote additional funds to demonstrating the worth of their medications to “health technology assessment (HTA) agencies, insurers and payers.” Drug firms also have to cope with the escalating need for cost-efficient care, increasingly complex value metrics, reduced prices and lower repayments. Along with the influx of generic drugs and “high-value” medications that fight certain conditions, “the middle of the pharmaceuticals market” is feeling the pressure. Several strategies can help drug manufacturers cope:

  • Change research and development (R&D) processes to ensure they’re focused on creating economic, social or innovative value.
  • Make gathering information during drug trials as well as after...

More on this topic

By the same author

Industries in 2019
8
Order and Progress?
8
The Global Liveability Index 2018
8
The Hinrich Foundation Sustainable Trade Index
8
Preparing for Disruption
9
Trade War Brewing?
8
A Digital Future
7
M&A in a Changing World
8
Turning Tides
8
Changes on the Institutional Investment Horizon
7
The Marriage of High Tech and High Finance
7
Innovation in Investment
9
China’s Supply-Side Structural Reforms
9
Symbiosis
8
Worldwide Cost of Living 2017
7
2016 The Year in Crisis
7
Innovation in Life Sciences
9
Democracy Index 2016
9
The Chinese Consumer in 2030
9
Towards Disaster-Risk Sensitive Investments
7
Industries in 2017
8
Managing Risk in Challenging Economic Times
8
Terms of Trade
7
The Workforce of the Future
8
Global Microscope 2016
8
“One Belt, One Road”
8
US Mid-Market Enterprises
7
Global Food Security Index 2016
8
Latin America’s Innovation Gap
8
The Hinrich Foundation Sustainable Trade Index 2016
8
Factors
7
Out and Down
8
Retail Banking
7
Europe Stretched to the Limit
8
Worldwide Cost of Living 2016
7
The Well-Connected Treasurer
7
All That Glitters
8
Governance, Cost and Sustainable Investing
7
Democracy Index 2015
8
Industries in 2016
8
Rethinking Risk in a More Uncertain World
7
The Disruption of Banking
8
The Never-ending Sale
8
After the Freefall, What to Expect from Commodity Prices
8
A Delicate Stage
8
Cultivating Sources
7
The Wealthy Migrant
7
Financing the Fragile Economic Recovery
7
Long-Term Macroeconomic Forecasts
8
The Cost of Inaction
9
The Blue Economy
8
Chinese Investment in Developed Markets
8
Private Sector Development in the Caribbean
7
Prospects and Challenges on China’s ‘One Belt, One Road’
8
Generation ¥
8
Future Cities
8
Digital Adoption in the Insurance Sector
8
Future Factors
7
Spotlight on the New Wealth Builders
8
The Road from Principles to Practice
7
Singapore
8
Worldwide Cost of Living 2015
8
Redefining Banking to Survive and Thrive in a Digital World
7
The Future of Business: Supply Chains
7
Democracy Index 2014
8
Still Making It
8
Retail Banks and Big Data
7
Navigating the Waters of Foreign Exchange and International Payments
7
Industries in 2015
8
Global Challenges in Asset Management
7
The Business of Cheaper Oil
8
China Going Global Investment Index
7
Financial Services: United States of America
6
Global Microscope 2014
8
Evolution of Work and the Worker
7
Cyber Incident Response
8
Business Environment Rankings
7
The Business Environment in Gulf Co-Operation Council Countries
8
Consumer Goods and Retail
7
United Kingdom
7
Financial Services
8
Energy
8
Japan
7
Germany
7
Future Factors
7
Worldwide Cost of Living 2014
7
China’s Urban Dreams, and the Regional Reality
9
The Search for Growth
8
Brazil
8
Is 75 the New 65?
8
Succeeding in a Value-Based Environment
8
Industries in 2014
8
The End Isn't Nigh
8
Diminishing Dependence
8
China
8
World Risk Alert April 18th 2013
8
Telecommunications
8
Women’s Economic Opportunity 2012
8
Consumer Goods and Retail
7

Customers who read this summary also read

Epidemics and Economics
8
The Value of Everything
8
Capitalism’s Greatest Weakness?
8
The Global Risks Report 2018
9
Crypto and Cannabis Are the Perfect Post-Crisis Bubbles
8
The American Economy Is Rigged
8

Related Channels

Comment on this summary